Takeda Pharmaceutical Files 6-K for December 2024
Ticker: TKPHF · Form: 6-K · Filed: Dec 18, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Dec 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, reporting-obligation
TL;DR
Takeda filed its monthly 6-K, confirming its foreign private issuer status and 20-F filing requirement.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on December 18, 2024, reporting its status as a foreign private issuer. The filing indicates that Takeda is submitting this report for the month of December 2024 and is required to file annual reports under Form 20-F.
Why It Matters
This filing confirms Takeda's ongoing reporting obligations as a foreign private issuer with the SEC, providing transparency to investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 0001395064-24-000174 (accession_number) — Filing identifier
- 20241218 (date) — Filing date
- 001-38757 (sec_file_number) — Takeda's SEC file number
- Form 20-F (document_type) — Required annual report form
- Form 6-K (document_type) — Current report form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically to provide information that the registrant makes or is required to make public in its home country.
What is Takeda Pharmaceutical Company Limited's SEC file number?
Takeda Pharmaceutical Company Limited's SEC file number is 001-38757.
Which form does Takeda file for its annual reports?
Takeda indicates it files its annual reports under cover of Form 20-F.
On what date was this Form 6-K filed?
This Form 6-K was filed on December 18, 2024.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 18.1 · Accepted 2024-12-18 06:01:36
Filing Documents
- form6k_121824.htm (6-K) — 39KB
- exhibit991_121824.htm (EX-99.1) — 25KB
- 0001395064-24-000174.txt ( ) — 65KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date December 18, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Details of the Amendment Cover Document Filed Amendment Extraordinary Report Filed with Director, Kanto Local Finance Bureau Filing Date December 18, 2024 Company Name Takeda Pharmaceutical Company Limited Title and Name of Representative Christophe Weber, Representative Director, President Chief Executive Officer Address of Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka (The above address is the registered head office location and the ordinary business operations are conducted at the "Nearest Place of Contact") Telephone Number Not applicable Name of Contact Person Not applicable Nearest Place of Contact 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo (Global Headquarters) Telephone Number +81-3-3278-2111 (Main telephone number) Name of Contact Person Norimasa Takeda, Head of Global Consolidation and Japan Reporting, Global Finance Please for public inspection Takeda Pharmaceutical Company Limited (Global Headquarters) (1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo) Tokyo Stock Exchange, Inc. (2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo) Nagoya Stock Exchange, Inc. (8-20, Sakae 3-chome, Naka-ku, Nagoya) Fukuoka Stock Exchange (14-2, Tenjin 2-chome, Chuo-ku, Fukuoka) Sapporo Stock Exchange (14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo) 1. Reason for Submitting the Amendment Extraordinary Report On September 26, 2024, the Company submitted an Extraordinary Report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of the Cabinet Office Ordinance concerning Disclosure of Corporate Affairs, etc. to repor